BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $6990.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06968585-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:A166 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.\, 
 Ltd. $6990.HK
DESCRIPTION:A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patient
 s With HER2-Positive Unresectable or Metastatic Breast Cancer Previously T
 reated With Trastuzumab and Taxane Therapy\n\nPrimary completion date: 202
 6-11-30 (estimated)\nOriginally planned: 2025-11-30 (+12.0 months)\nPhase 
 3 · Oncology · HER2-positive Breast Cancer\nEnrollment: 365 · Sites: 1\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT06968585\nhttps://clinicaltrials.gov/study/NCT06968585
URL:https://datacutoff.com/radar.html?nct=NCT06968585
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~SKB264 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.
 \, Ltd. $6990.HK
DESCRIPTION:A Study of SKB264 in Combination With Pembrolizumab Versus Chem
 otherapy in Combination With Pembrolizumab as First-Line Treatment for PD-
 L1 Negative Patients With Locally Advanced…\n\nPrimary completion date: 
 2026-12 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncology
  · Non-Small Cell Lung Cancer\nEnrollment: 432 · Sites: 81\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T06711900\nhttps://clinicaltrials.gov/study/NCT06711900
URL:https://datacutoff.com/radar.html?nct=NCT06711900
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631262-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SKB264 readout (P2) · Sichuan Kelun-Biotech Biopharmaceutical Co.\
 , Ltd. $6990.HK
DESCRIPTION:SKB264 Monotherapy in Selected Subjects With Advanced Solid Tum
 ors\n\nPrimary completion date: 2026-12-30 (estimated)\nOriginally planned
 : 2024-10-30 (+26.0 months)\nPhase 2 · Oncology · Selected Subjects With
  Advanced Solid Tumors\nEnrollment: 321 · Sites: 1\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05631262
 \nhttps://clinicaltrials.gov/study/NCT05631262
URL:https://datacutoff.com/radar.html?nct=NCT05631262
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKB264 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.\
 , Ltd. $6990.HK
DESCRIPTION:Study of SKB264 for Locally Advanced\, Recurrent or Metastatic 
 HR+/HER2- Breast Cancer\n\nPrimary completion date: 2026-12-31 (estimated)
 \nOriginally planned: 2026-03-31 (+9.0 months)\nPhase 3 · Oncology · Met
 astatic Breast Cancer\nEnrollment: 376 · Sites: 1\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06081959\
 nhttps://clinicaltrials.gov/study/NCT06081959
URL:https://datacutoff.com/radar.html?nct=NCT06081959
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019675-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:SKB518 readout (P2) · Sichuan Kelun-Biotech Biopharmaceutical Co.\
 , Ltd. $6990.HK
DESCRIPTION:A Study of SKB518 in Patients With Lung Cancer\n\nPrimary compl
 etion date: 2027-02-20 (estimated)\nOriginally planned: 2027-06-20 (-3.9 m
 onths)\nPhase 2 · Oncology · Lung Carcinoma\nEnrollment: 192 · Sites: 1
 7\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT07019675\nhttps://clinicaltrials.gov/study/NCT07019675
URL:https://datacutoff.com/radar.html?nct=NCT07019675
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~SKB264 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.
 \, Ltd. $6990.HK
DESCRIPTION:A Study of SKB264 Versus Investigator's Choice Chemotherapy in 
 Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast 
 Cancer\n\nPrimary completion date: 2027-04 (estimated) — month only\, sh
 own on the 1st\nOriginally planned: 2026-07 (+9.0 months)\nPhase 3 · Onco
 logy · Triple Negative Breast Cancer\nEnrollment: 537 · Sites: 1\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06279364\nhttps://clinicaltrials.gov/study/NCT06279364
URL:https://datacutoff.com/radar.html?nct=NCT06279364
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~SKB264 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.
 \, Ltd. $6990.HK
DESCRIPTION:A Study of SKB264 in Combination With Osimertinib Versus Osimer
 tinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\,
  Locally Advanced or Metastatic Non-Squamou…\n\nPrimary completion date:
  2027-05 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncolog
 y · Non-Small Cell Lung Cancer\nEnrollment: 420 · Sites: 1\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T06670196\nhttps://clinicaltrials.gov/study/NCT06670196
URL:https://datacutoff.com/radar.html?nct=NCT06670196
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308106-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SKB571 for injection readout (P2) · Sichuan Kelun-Biotech Biopharm
 aceutical Co.\, Ltd. $6990.HK
DESCRIPTION:A Phase II Clinical Study of SKB571 as Monotherapy in Patients 
 With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Ab
 normalities\n\nPrimary completion date: 2027-06-30 (estimated)\nPhase 2 ·
  Oncology · Non-small Lung Cancer\nEnrollment: 70 · Sites: 1\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT07308106\nhttps://clinicaltrials.gov/study/NCT07308106
URL:https://datacutoff.com/radar.html?nct=NCT07308106
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~SKB264 readout (P3) · Sichuan Kelun-Biotech Biopharmaceutical Co.
 \, Ltd. $6990.HK
DESCRIPTION:A Study of SKB264 Versus Investigator's Choice of Chemotherapy 
 in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metastatic 
 HR+/HER2- Breast Cancer Who Have Previously …\n\nPrimary completion date
 : 2027-07 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncolo
 gy · Metastatic Breast Cancer\nEnrollment: 430 · Sites: 2\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 07071337\nhttps://clinicaltrials.gov/study/NCT07071337
URL:https://datacutoff.com/radar.html?nct=NCT07071337
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan readout (P2) · Sichuan Kelun-Biotech Bioph
 armaceutical Co.\, Ltd. $6990.HK
DESCRIPTION:Phase II Study of Sacituzumab Tirumotecan in Combination With O
 simertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal
  Growth Factor Receptor (EGFR)-Mutated Non…\n\nPrimary completion date: 
 2027-08-31 (estimated)\nPhase 2 · Oncology · Non-Small Cell Lung Cancer\
 nEnrollment: 30 · Sites: 1\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://datacutoff.com/radar.html?nct=NCT07329322\nhttps://clinicaltrials
 .gov/study/NCT07329322
URL:https://datacutoff.com/radar.html?nct=NCT07329322
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564466-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SKB571 for injection readout (P2) · Sichuan Kelun-Biotech Biopharm
 aceutical Co.\, Ltd. $6990.HK
DESCRIPTION:A Study of SKB571 in Participants With Gastrointestinal Tumors\
 n\nPrimary completion date: 2027-08-31 (estimated)\nPhase 2 · Oncology ·
  Gastrointestinal Tumors\nEnrollment: 160 · Sites: 26\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07564
 466\nhttps://clinicaltrials.gov/study/NCT07564466
URL:https://datacutoff.com/radar.html?nct=NCT07564466
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299825-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:A166 readout (P2) · Sichuan Kelun-Biotech Biopharmaceutical Co.\, 
 Ltd. $6990.HK
DESCRIPTION:A Study of A166 in Patients With HER2-Positive Unresectable or 
 Metastatic Breast Cancer\n\nPrimary completion date: 2027-09-20 (estimated
 )\nPhase 2 · Oncology · Her 2 Positive Breast Cancer\nEnrollment: 40 · 
 Sites: 1\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT07299825\nhttps://clinicaltrials.gov/study/NCT07299
 825
URL:https://datacutoff.com/radar.html?nct=NCT07299825
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
